Clinical Trial

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma

Study acronym: ANSWER
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2024 (before its estimated June 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy for patients with advanced esophageal squamous cell carcinoma (Answer): A randomized two-arm clinical study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-01-14; most recent amendment 2024-12-26.
Status change: Not Yet Recruiting → Recruiting 2022-09-27
Trial Details
NCT Number NCT05214222
Lead Sponsor Nanfang Hospital, Southern Medical University
Conditions Advanced Esophageal Squamous Cell Carcinoma
Enrollment 100 participants
Start Date 2022-09-02
Primary Completion 2026-06-02 (estimated)
Study Completion 2028-09-02 (estimated)
Updated on ClinicalTrials.gov 2024-12-30